Novartis and Diagnostics Srl recall meningitis vaccine kit

Published: 26-Feb-2009
Pharmaceutical

Novartis Vaccines and Diagnostics Srl are recalling batches of Menjugate Kit as a precaution after samples from two batches were found to contain a bacterium.


Novartis Vaccines and Diagnostics Srl are recalling batches of Menjugate Kit as a precaution after samples from two batches were found to contain a bacterium.

The precautionary move follows an initial failure of a sterility test carried out as part of a shipping validation study of the batch of aluminium hydroxide solvent used in them. This batch passed its sterility test at the time of release.

The recalled batches of the Menjugate Kit were manufactured in Italy and then shipped to various countries. Some 21,000 doses have already been removed from the shelves.

Novartis are investigating the root cause for the non-conforming sterility result.

See more

You may also like

Research & Development

Novartis bolsters kidney disease portfolio with Regulus Therapeutics acquisition

Read more
Through the acquisition, Novartis will gain access Regulus Therapeutics' oligonucleotide, farabursen, which is designed for the treatment of ADPKD

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  3. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  4. CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
  5. Servier and IDEAYA Biosciences join forces to bring a promising new eye cancer treatment to patients across the globe Servier and IDEAYA Biosciences have entered into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Novartis bolsters kidney disease portfolio with Regulus Therapeutics acquisition

Through the acquisition, Novartis will gain access Regulus Therapeutics' oligonucleotide, farabursen, which is designed for the treatment of ADPKD
Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Manufacturing

Novartis opens facility for innovative cell and gene therapies in Switzerland

New building in Stein also hosts the production of difficult-to-manufacture solid dosage forms
Finance

Lonza to buy sterile drug product fill-finish facility from Novartis

Swiss CDMO bids to keep management and operations teams and manufacture for Novartis at the site in Stein
Regulatory

Novartis starts voluntary recall after peanut contamination scare

Three lots of Promacta 12.5 mg for oral suspension to the consumer level have been recalled due to cross-contamination risk
Research & Development

Blackstone and Novartis: Joint venture targets cardiovascular disease

Anthos Therapeutics enters the market with US$250 million backing from Blackstone and an anti-thrombotic licensed from Novartis
Subscribe now